## **Presentation Type:**

Poster Presentation

Comparative Usability of Three Platforms for Collecting Standard Precautions Surveillance Data

<u>Cara Thurman, Columbia University;</u> Amanda Hessels, Columbia University, School of Nursing

Background: Although standard precautions are considered a building block in the prevention of healthcare-associated infections (HAIs) and bloodborne pathogen (BBP) exposures, little is known about the rate of adherence to standard precautions among healthcare workers in US acute-care hospitals and the processes used for measurement and surveillance. **Methods:** We evaluated the development and usability of electronic platforms to collect standard precautions surveillance data in support of the Simulation to Improve Infection Prevention and Patient Safety (SIPPS) Trial. SIPPS is a 5-year group-randomized group-interventional study to develop and test a simulation intervention to improve provider performance of standard precautions and prevent HAIs and occupational BBP exposures. In the pilot study, standard precautions adherence data were collected and validated using the Standard Precautions Observational Tool (SPOT) in a paper format. Adherence was measured using 10 indicators across the categories of hand hygiene, personal protective equipment, linen handling, and sharps disposal. The SPOT allows users to observe healthcare workers providing routine care and to record when an SP action is indicated and whether it was completed or missed. The data did not contain personally identifiable information or protected health information. The aim of this project was to design an electronic version of the SPOT that is simple and affordable to create, allows for rapid and structured data collection, and can be disseminated for broad standardization of standard precautions surveillance. Results: Three electronic platforms, including 2 survey-based platforms (Qualtrics and REDCap) and 1 websitebased platform (Google), were evaluated for the following characteristics: (1) design interface, (2) customizability, (3) data entry speed, (4) accessibility, and (5) total cost. Both survey platforms performed well in design interface, allowing for a no- or low-code design and offered mobile-friendly formats. Rigid survey formats created obstacles in customization and rapid data collection, involving large amounts of scrolling or screen advancement. Survey-based platforms also required a subscription or access fee. Conversely, the websitebased platform had a more challenging design interface but was easily customizable with low-level knowledge of hypertext mark-up language (HTML) and application programming interface deployment. The website platform allowed for a single screen view, mobile-

	qualtrics. <sup>™</sup>	REDCap	Google
Design Interface			
Customizability			
Accessibility			
Data Entry Speed			
Total Cost			

Fig. 1

**2** 41 Suppl 1; 2020

phone–friendly design, and rapid data collection. It was developed using freely available resources. **Conclusions:** A website-based HTML form allows for faster data collection and a higher level of customization than survey-based platforms and can be designed and implemented free of cost using minimal web-development skills. This surveillance methodology will be field tested for fidelity of implementation and for broad use in surveillance.

Funding: The Agency for Healthcare Research and Quality provided Funding: for this study (grant no. 1R18HS026418).

**Disclosures:** Amanda Hessels reports that she is the primary investigator for the studies titled "Impact of Patient Safety Climate on Infection Prevention Practices and Healthcare Worker and Patient Outcomes" (grant no. DHHS/CDC/NIOSH 1K01OH011186 to Columbia University) and "Simulation to Improve Infection Prevention and Patient Safety: The SIPPS Trial (AHRQ grant no. R18: 1R18HS026418 to Columbia University)


Doi:10.1017/ice.2020.1110

## **Presentation Type:**

Poster Presentation

Democratizing Sequencing for Infection Control: A Scalable, Automated Pipeline for WGS Analysis for Outbreak Detection Mohamad Sater, Day Zero Diagnostics; Timothy Farrell, Day Zero Diagnostics; Febriana Pangestu, Day Zero Diagnostics; Ian Herriott, Day Zero Diagnostics; Melis Anahtar, Massachusetts General Hospital; Doug Kwon, Massachusetts General Hospital; Erica Shenoy, Massachusetts General Hospital; David Hooper, Massachusetts General Hospital; Miriam Huntley, Day Zero Diagnostics

**Background:** Whole-genome sequencing (WGS) is well established as a high-resolution method for measuring bacterial relatedness to better understand infection transmission in cases of healthcare-associated infections (HAIs). However, sequencing is still rarely used in HAI investigations due to a lack of access to computational analysis platforms with actionable turnaround times. Single-nucleotide polymorphism (SNP) analysis is typically used to determine bacterial relatedness. However, SNP-based methods often require a suite of bioinformatics tools that can be difficult to use and interpret without the expertise of a trained computational biologist. These obstacles become more significant in the case of prospective, real-time surveillance of HAIs, which can require the analysis of a large number of isolates. To enable the use of WGS for proactive determination of infection outbreaks, a rapid, automated method that can scale to large data sets is needed. Methods: Here, we demonstrate the capabilities of ksim, a novel automated algorithm to determine the clonality of bacterial samples using WGS. *ksim* measures the number of shared *k*mers (genomic subsequences of length k) between bacterial samples to determine their relatedness. ksim also filters out accessory genomic regions, such as plasmids, that can confound genetic relatedness estimates. We benchmarked the accuracy and speed of *ksim* relative to an SNP-based pipeline on simulated data sets (with sequencing reads generated in silico) and on 9 clinical-cluster data sets (6 publicly available and 3 real-time data sets from Massachusetts General Hospital [MGH]). We also used ksim to determine the relatedness of >5,000 historical clinical bacterial isolates from MGH, collected between 2015 and 2019. Results: ksim first preprocesses raw sequencing data to generate a common data structure, after which it computes the genomic distance between bacterial samples in ~0.2 seconds in simple cases and in ~4 seconds in complex cases when accessory genome filtering is required. In simulations across 5 species, ksim determined clonality (defined as <40 SNPs) with high accuracy (sensitivity, 99.7% and specificity, 99.6%). ksim performance on 9



**ksim** clustering of >3000 *E. coli* clinical samples.

Patient clusters based on isolate genomic clonality identified by *ksim*. Each yellow circle represents a patient, an edge between two circles denotes an *E. coli* clonal pair, non-clonal pairs not shown.

Fig. 1.

clinical HAI data sets demonstrated its sensitivity (99.4%) and specificity (90.8%) compared to an SNP-based pipeline. *ksim* efficiently analyzed >5,000 clinical samples from MGH and found previously unidentified transmission clusters. **Conclusions:** *ksim* shows promise for rapid clonality determination in HAI outbreaks and has the potential to scale to tens of thousands of samples. This method could enable infection control teams to use WGS for prospective outbreak detection via an automated computational pipeline without the need for specialized computational biology training.

**Funding:** Day Zero Diagnostics and the NIH provided **Funding:** for this study.

**Disclosures:** Mohamad Sater reports salary from Day Zero Diagnostics.

Doi:10.1017/ice.2020.1111

## **Presentation Type:**

Poster Presentation

Evaluation of Autoclaving CAT: A Infectious Substance Packaging during the Ebola Crisis in the United States Edward Krisiunas, WNWN International; Gina Vallone-Hood, Florida Department of Health; Alan Woodard, New York State

Department of Environmental Conservation; Neil Norrell, United States Environmental Protection Agency

Background: During the 2014 US Ebola crisis, an unprecedented amount of biohazardous waste was generated during patient care; healthcare facilities were overwhelmed by large volumes of waste. Few facilities had on-site waste treatment; therefore, waste was packaged and sent off site for incineration and disposal in Port Arthur, Texas, at a significant cost. Shipping this waste off site required the use of the US Department of Transportation (USDOT) Hazardous Materials (HMR 49 CFR) category A triple packaging for infectious substances. The most common treatment method for biohazardous waste in the United States is via commercial autoclaves. Because Category A waste packaging had not been tested to ensure effective treatment, we conducted autoclave efficacy studies to evaluate the various types of Category A packaging containing surrogate Ebola waste. If successful, this would potentially provide additional treatment options in the United States. Methods: Testing was conducted at commercial locations in 3 states: New York, Pennsylvania, and Florida. Various types of Category A packaging were obtained (Fig. 1). Waste loads were comprised of Ebola patient treatment material and included personal protective equipment, sharps containers, suction canisters, drapes, and associated items. Configured packaging was placed into autoclave bins to be processed. Each package tested included a biological indicator, a class 5 integrator. Where possible, thermocouples were added to record the thermoprofile of the waste. Initially, a modified cycle was tested (a prevacuum cycle followed by exposure to steam at 138°C for 60 minutes) and a postvacuum cycle. Cycle times were adjusted based upon initial results. Results: The initial New York autoclave was tested from a cold start (no vessel preheating) resulting in a failure to obtain efficacy (Fig. 1). Successful results were no growth in recovered biological indicators, acceptable color change in integrators, and reaching and holding temperatures >121°C for 30 minutes. After making modifications to treatment cycles, which included preheating of vessels, multiple prevacuum steps and a hold time of 60 minutes, successful results were achieved in testing conducted at the treatment plants in Pennsylvania and Florida. Conclusions: Commercial autoclaves can be effective in treating Category A biohazardous waste. Each autoclave considered for treatment requires a validation process using the types of packaging containing the waste, biological indicators, integrators, and thermocouples to present a complete assessment of the treatment process.

**Funding:** Three companies provided support for this study: Approved Storage & Waste Hauling, Daniels International, and ProMed Solutions.



Fig. 1